Glenmark Pharmaceuticals Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Glenmark Pharmaceuticals Limited
Glenmark is set to roll out its allergic rhinitis nasal spray Ryaltris in three South East Asian countries following an exclusive licensing agreement with Lotus. The company expects Ryaltris to have a significant role to play in its growth over the coming years.
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Glenmark is celebrating a “major milestone,” after its Ryaltris nasal spray to treat seasonal allergic rhinitis was approved by the FDA. Hikma will handle commercialization in the US, as part of its continued specialty push in the market.
India authorizes molnupiravir for restricted emergency use in COVID-19, marking the arrival of around a dozen “affordable” generics of Merck & Co. and Ridgeback Biotherapeutics' oral antiviral. Physicians say data are “pretty compelling” notwithstanding the narrow FDA nod.
- Drug Delivery
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
- Drug Discovery Tools
- Other Names / Subsidiaries
- Integrace Private Limited
- Ichnos Sciences